NCT02144584Active, not recruitingEarly phase 1
Memantine for Enhanced Stroke Recovery
Pilot Study of Memantine for Enhanced Stroke Recovery
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 27 Jan 2014
- Start date
- 1 Jan 2014
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- University of Utah
- Diseases
- Stroke
- NCT number
- NCT02144584
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 1 Jan 2014 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior clinical stroke with residual symptoms on the same side as the current symptoms that would interfere with outcomes of this study
- Documented severe renal impairment (CrCl \< 30 ml/min) Blood tests will be performed prior to study procedures that will ensure patients do not have renal impairment if not done as part of clinical care.
Other illness
- subarachnoid hemorrhage, subdural hemorrhage or other cause of symptoms other than ischemic or hemorrhagic stroke
- Infratentorial location of stroke (brainstem or cerebellum)
- NIH Stroke Scale \>20 at the time of randomization
- History of dementia that will interfere with rehabilitation
- Pre or post-stroke use of memantine or amantadine
- Comorbid neurologic disease that would interfere with the results including but not limited to Multiple Sclerosis, neurodegenerative diseases, spinal cord disease, and central nervous system cancer.
- Documented severe hepatic impairment (Child-Pugh score \> 6) or severe hepatic disease (hepatitis)
Other
- Contraindications to taking memantine XR in pill form
- Moribund or not expected to live 6 months
- Severe cognitive deficits or pre-morbid function causing inaccurate neurologic assessment or inability to complete the initial assessment
- Patients who are pregnant or breast feeding
Who the study is looking for
- Age \>18 years old
- Randomization between 3 days-8 weeks days of stroke symptom onset
- Arm weakness severe enough to warrant inpatient or outpatient occupational therapies
- Able to voluntarily move affected UE
- Living independently prior to their stroke
- Image-confirmed ischemic stroke (MRI or CT)
- Supratentorial location of stroke
- Fugl-Meyer Upper Extremity Score of 50 or less and/or Fugl Meyer Lower Extremity Score of 28 or less
- Ability to swallow pills
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.